CRNO B
6.08 SEK
-0.01 (-0.16%)
Year-end Report 2025

Entering global development phase

Year-end Report 2025

"2025 marked a pivotal year for Cereno Scientific. As we enter 2026, our priority is clear: initiate the global Phase IIb trial with CS1, maintain close regulatory interaction and execute the trial with operational excellence."

Sten R. Sörensen

CEO

Learn more

Our equity story

Investment case

Stay up to date

Receive email alerts

To stay up to date with our development, subscribe to our news flow.

Subscribe
Investor questions

Contact

Investor questions

Tove Bergenholt, Head of IR & Communications

Email: [email protected]

Phone: +46(0)732-366 246